 | • レポートコード：B-MOR-05036 • 出版社/出版日：Mordor Intelligence / 2018年3月 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、抗真菌薬の世界市場について調べ、抗真菌薬の世界規模、市場動向、市場環境、薬剤タイプ別分析、治療適用別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・抗真菌薬の世界市場インサイト ・抗真菌薬の世界市場環境 ・抗真菌薬の世界市場動向 ・抗真菌薬の世界市場規模 ・抗真菌薬の世界市場規模：薬剤タイプ別 ・抗真菌薬の世界市場規模：治療適用別 ・抗真菌薬の世界市場：地域別市場規模・分析 ・抗真菌薬の北米市場規模・予測 ・抗真菌薬のアメリカ市場規模・予測 ・抗真菌薬のヨーロッパ市場規模・予測 ・抗真菌薬のアジア市場規模・予測 ・抗真菌薬の日本市場規模・予測 ・抗真菌薬の中国市場規模・予測 ・抗真菌薬のインド市場規模・予測 ・抗真菌薬の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global anti-fungal drugs market is expected to register a CAGR of 3.6% during the forecast period, 2018 to 2023. Anti-fungal drugs are used to treat the fungal infections which are caused by soggy, unhygienic, and unclean environments in which the microscopic organisms such as fungus thrive. Fungi multiply by spreading microscopic spores.
Increasing Number of Anti-Fungal Drugs as Over-The-Counter (OTC)
With rising popularity of Over-The-Counter (OTC) drugs, many patients are preferring OTC drugs because these over the counter drugs are obtaining without a prescription from a healthcare professional. Numerous common and harmless fungal infections are left untreated by patients, owing to medical costs and logistical constraints. These have directly contributed to the rise in the usage of OTC drugs, owing to their ease of availability. According to the Consumer Healthcare Products Association, more than 81% of adults use OTC medicines as their first response to minor ailments. The increased usage of OTC drugs has further contributed to the rise in anti-fungal drug sales over the years. And the other factors such as increasing awareness among the people regarding the fungal infection, and increasing number of the immune-compromised aged population are driving the market growth.
Presence of Generics and Government Regulations in the Pharmaceutical Industry
Although there is an increase in the sales for anti-fungal generic drugs, the market value of anti-fungal drugs has decreased, as the price of generics is almost 20 to 50 % of the branded drugs. To meet the market value, the sales of generics must be increased by at least four times to that of the branded drugs. Even with the increasing volume of generic anti-fungal drug sales, the overall market value of anti-fungal drugs has reduced. The increased usage of generic anti-fungal drugs will restrain the growth of the market in the forecast period.
The pricing regulations by various governments, their strict regulatory frameworks for the approval of anti-fungal drugs, is acting as a restraining factor along with the high penetration of conventional drugs used for treatment is hindering the growth of the global anti-fungal drugs market.
North America to dominate the Market
North America dominates the market due to increasing awareness of fungal infections with the growing incidence of antifungal infections and increasing government and corporate funding in the industry. While Asia-Pacific was estimated to register the fastest CAGR through the forecast period, 2018-2023.
Key Developments in the Market
• October 2017: Gilead Sciences has Acquired the Kite Pharma, Inc.
Major Players: ABBOTT LABORATORIES, PFIZER, GLAXOSMITHKLINE, BAYER HEALTHCARE, NOVARTIS, SANOFI-AVENTIS, MERCK & CO., KRAMER LABORATORIES, ENZON PHARMACEUTICALS, GILEAD, amongst others.
Reasons to Purchase this Report
• Current and future anti-fungal drugs market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Degree of Competition
5.3.4 Threat of Substitution
5.3.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Number of Antifungal Drugs as Over-The-Counter (OTC)
6.1.2 Increasing Awareness about the Myriad Fungal Infections
6.1.3 Increasing Government and Corporate Funding
6.1.4 Rise in Number of Immune-Compromised Aged Population
6.2 Market Restraints
6.2.1 High Penetration of Conventional Drugs Used For Treatment
6.2.2 Presence of Generics and Government Regulations in Pharmaceutical Industry
6.3 Opportunities
6.3.1 Introduction of New Anti-Fungal Drugs
6.4 Challenges
6.4.1 Increasing Resistance to Anti-Fungal Drugs
7. Market Segmentation
7.1 By Drug Type
7.1.1 Echinocandins
7.1.1.1 Pneumocandins
7.1.1.2 Caspofungin
7.1.1.3 Micafungin
7.1.1.4 Anidulafungin
7.1.1.5 Others
7.1.2 Azoles
7.1.2.1 Voricanazole
7.1.2.2 Imidazoles
7.1.2.3 Triazoles
7.1.2.4 Thiazoles
7.1.2.5 Others
7.1.3 Allylamines
7.1.4.1 Lamisil
7.1.4.2 Terbinafine
7.1.4.3 Others
7.1.4 Others
7.1.4.1 Benzoic Acid
7.1.4.2 Ciclopirox
7.1.4.3 Greisiofulvin
7.2 By Therapeutic Indication
7.2.1 Aspergillosis
7.2.2 Dermatophytosis
7.2.3 Candidiasis
7.2.4 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 US
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 Germany
7.3.2.2 UK
7.3.2.3 France
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe (RoE)
7.3.3 Asia-Pacific
7.3.3.1 Japan
7.3.3.2 China
7.3.3.3 India
7.3.3.4 South Korea
7.3.3.5 Australia
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC Countries
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America (Rosa)
8. Competitive Landscape
8.1 Mergers & Acquisitions
8.2 Agreements, Collaborations & Partnerships
8.3 New Product Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Pfizer
9.3 GlaxoSmithKline
9.4 Bayer Healthcare
9.5 Novartis
9.6 Sanofi-Aventis
9.7 Merck & Co.
9.8 Kramer Laboratories
9.9 Enzon Pharmaceuticals
9.10 Gilead
10. Future of the Market